Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.


In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development, Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion."

Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Secondary endpoints of the trial include clinical evaluation of patient response in both treatment arms by tumor biopsy hyaluronan (HA) status.

Halozyme is also developing a HA diagnostic tool that will help evaluate potential treatment benefit based on HA levels for use in the randomized Phase 2 trial. Clinically validating this HA-diagnostic approach in the pancreatic cancer trial may also provide proof-of-concept for use of PEGPH20 in other HA-rich tumor types.

Halozyme Abstracts at ASCO:

  • Poster Presentation/Discussion: (E Hall D1): "A Phase 1b Study of Gemcitabine Plus PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in Patients with Stage IV Previously Untreated Pancreatic Cancer" will be presented by Sunil R. Hingorani M.D ., Ph.D., Fred Hutchinson Cancer Research Center on Monday, June 3 at 1:15PM-5:15PM CDT; discussion from 4:45 PM-5:45PM CDT. (Abstract #4010)
  • Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

*33 percent response rate reported in the ASCO abstract based on partial data available at the time of abstract submission.

About Pancreatic Cancer
In most patients diagnosed with metastatic pancreatic adenocarcinoma, survival rates are the lowest of any cancer. In 2013, it is estimated that almost 45,000 new cases of pancreatic cancer will be diagnosed. About one-in-78 people in the U.S. will develop the disease, affecting equal numbers of men and women, almost always after the age of 45. Its tendency to spread prior to diagnosis makes it the fourth deadliest cancer with a less than six percent five-year relative survival rate, with more than 38,000 people succumbing to the disease each year.1-2

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible benefits and attributes of PEGPH20, the anticipated enrollment of patients and possible outcomes for the referenced Phase 2 clinical trial, the possible method of action of PEGPH20 and the anticipated presentation of data from Halozyme's Phase 1b trial and the development of the HA diagnostic tool and the potential uses of such tool. The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2013. Halozyme does not undertake to update these forward-looking statements.

1. American Cancer Society, Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
2. Pancreatic Cancer, American Cancer Society,  Accessed April 18, 2013


Investor Contact:
Kurt Gustafson
Halozyme Therapeutics

Media Contact:
Nurha Hindi
Hill+Knowlton Strategies

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):